AMPH

Amphastar Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

27.890

+0.25(0.904%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

28.240

Open

27.880

VWAP

27.97

Vol

424.68K

Mkt Cap

1.30B

Low

27.610

Amount

11.88M

EV/EBITDA(TTM)

7.02

Total Shares

48.90M

1.66B

EV/OCF(TTM)

10.41

P/S(TTM)

1.92

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

176.00M

+3.21%

0.750

+1.35%

195.39M

+4.76%

0.908

-1.27%

186.89M

-2.26%

0.852

-11.28%

Estimates Revision

The market is revising Upward the revenue expectations for Amphastar Pharmaceuticals, Inc. (AMPH) for FY2025, with the revenue forecasts being adjusted by 0.76% over the past three months. During the same period, the stock price has changed by 13.01%.

Revenue Estimates for FY2025

Revise Upward

+0.76%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+6.7%

In Past 3 Month

Stock Price

Go Up

+13.01%

In Past 3 Month

5 Analyst Rating

14.02% Upside

Wall Street analysts forecast AMPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMPH is 31.80 USD with a low forecast of 25.00 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

3 Hold

0 Sell

Moderate Buy

14.02% Upside

Current: 27.890

Low

25.00

Averages

31.80

High

36.00

14.02% Upside

Current: 27.890

Low

25.00

Averages

31.80

High

36.00

BofA

Neutral

maintain

$28 -> $32

2025-08-26

Reason

BofA

Price Target

$28 -> $32

2025-08-26

maintain

Neutral

Reason

BofA raised the firm's price target on Amphastar to $32 from $28 and keeps a Neutral rating on the shares after increasing near-term forecasts to reflect the recent generic Venofer approval. Generic Venofer "looks like a good, but not great, generic product due to competitive dynamics at market formation," the analyst tells investors.

Needham

Serge Belanger

Hold

Buy

upgrade

$36

2025-08-12

Reason

Needham

Serge Belanger

Price Target

$36

2025-08-12

upgrade

Hold

Buy

Reason

Needham analyst Serge Belanger upgraded Amphastar to Buy from Hold with a $36 price target.

Needham

Hold

Buy

upgrade

$36

2025-08-12

Reason

Needham

Price Target

$36

2025-08-12

upgrade

Hold

Buy

Reason

Needham upgraded Amphastar (APMH) to Buy from Hold with a $36 price target. The company's AMP-002 is an iron sucrose injection product that received FDA approval as an equivalent to Venofer, a $515M annual sales product, the analyst tells investors in a research note. The firm says the only downside to the approval is an equivalent generic product by Viatris (VTRS) was also approved. Needham cites valuation for the upgrade of Amphastar and believes AMP-002 sales should help the company at least meet growth expectations for 2025 and 2026.

Piper Sandler

Neutral

downgrade

$30 -> $25

2025-08-08

Reason

Piper Sandler

Price Target

$30 -> $25

2025-08-08

downgrade

Neutral

Reason

Piper Sandler lowered the firm's price target on Amphastar to $25 from $30 and keeps a Neutral rating on the shares following quarterly results. The firm cites tempered generics sales estimates and lower gross margins. Competitive headwinds remain a challenge, Piper adds.

JPMorgan

Overweight -> Neutral

downgrade

$45 -> $30

2025-05-12

Reason

JPMorgan

Price Target

$45 -> $30

2025-05-12

downgrade

Overweight -> Neutral

Reason

JPMorgan downgraded Amphastar to Neutral from Overweight with a price target of $30, down from $45. The company has seen continued setbacks on the pipeline front, the analyst tells investors in a research note. The firm says that while Amphastar's generic business remains better positioned than some peers, both glucagon and epinephrine are eroding faster than the Street was expecting. As such, it sees better opportunities elsewhere in the space.

Wells Fargo

Cerena Chen

Overweight

downgrade

$40 -> $35

2025-05-08

Reason

Wells Fargo

Cerena Chen

Price Target

$40 -> $35

2025-05-08

downgrade

Overweight

Reason

Wells Fargo analyst Cerena Chen lowered the firm's price target on Amphastar to $35 from $40 and keeps an Overweight rating on the shares. The firm says that continued expectations for 2 launches this year despite recent CRLs is reassuring though it notes sales contribution would be more meaningful in 2026. Good Baqsimi and Primatene growth make Wells less concerned about competitive pressure elsewhere.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Amphastar Pharmaceuticals Inc (AMPH.O) is 8.34, compared to its 5-year average forward P/E of 15.03. For a more detailed relative valuation and DCF analysis to assess Amphastar Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

15.03

Current PE

8.34

Overvalued PE

19.69

Undervalued PE

10.37

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

8.79

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

10.56

Undervalued EV/EBITDA

7.01

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

2.59

Current PS

0.00

Overvalued PS

3.20

Undervalued PS

1.99

Financials

Annual

Quarterly

FY2025Q2

YoY :

-4.38%

174.41M

Total Revenue

FY2025Q2

YoY :

-23.60%

42.18M

Operating Profit

FY2025Q2

YoY :

-18.23%

31.03M

Net Income after Tax

FY2025Q2

YoY :

-12.33%

0.64

EPS - Diluted

FY2025Q2

YoY :

-63.88%

22.78M

Free Cash Flow

FY2025Q2

YoY :

-4.96%

49.59

Gross Profit Margin - %

FY2025Q2

YoY :

-39.14%

15.21

FCF Margin - %

FY2025Q2

YoY :

-14.51%

17.79

Net Margin - %

FY2025Q2

YoY :

-29.98%

11.70

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

37.6K

USD

3-6

Months

39.1K

USD

6-9

Months

144.5K

USD

0-12

Months

2.4M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

37.6K

USD

3-6

Months

39.1K

USD

6-9

Months

144.5K

USD

0-12

Months

2.4M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

AMPH News & Events

Events Timeline

2025-08-12 (ET)

2025-08-12

06:48:17

Amphastar announced FDA approval of iron sucrose injection

2025-07-23 (ET)

2025-07-23

08:08:48

Amphastar sees Q3 adjusted EPS 77c-79c, consensus 69c

2025-07-14 (ET)

2025-07-14

16:14:29

Amphastar announces multi-year expansion of California manufacturing operations

News

8.0

09-02NASDAQ.COM

Are Predictions from the Options Market Indicating a Surge in Amphastar Pharmaceuticals Stock?

9.0

08-12Benzinga

Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum

9.5

08-07NASDAQ.COM

Amphastar (AMPH) Q2 2025 Earnings Call Transcript

People Also Watch

Bank of NT Butterfield & Son Ltd

eXp World Holdings Inc

Brookfield Business Corp

United Natural Foods Inc

28.870

USD

-3.02%

FAQ

What is Amphastar Pharmaceuticals Inc (AMPH) stock price today?

The current price of AMPH is 27.89 USD — it has increased 0.9 % in the last trading day.

AMPH

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

AMPH News & Events

Events Timeline

News

People Also Watch

FAQ

What is Amphastar Pharmaceuticals Inc (AMPH) stock price today?

What is Amphastar Pharmaceuticals Inc (AMPH)'s business?

What is the price predicton of AMPH Stock?

What is Amphastar Pharmaceuticals Inc (AMPH)'s revenue for the last quarter?

What is Amphastar Pharmaceuticals Inc (AMPH)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Amphastar Pharmaceuticals Inc (AMPH)'s fundamentals?

How many employees does Amphastar Pharmaceuticals Inc (AMPH). have?

What is Amphastar Pharmaceuticals Inc (AMPH) market cap?